ANDA 208923, held by Avet Lifesciences. Sodium Nitroprusside.
As of Nov 16, 2026, ANDA 208923 (Sodium Nitroprusside), held by Avet Lifesciences, was first approved by FDA on Nov 8, 2022, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 8, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Nitroprusside25MG/ML ยท injectable;injection | Sodium Nitroprusside | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters